First Allied Advisory Services’s Juno Therapeutics, Inc. JUNO Stock Holding History

First Allied Advisory Services’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,136	Closed	-$244K	–	1179
2016 Q3	$244K	Sell	8,136 -13,016	-62%	-$405K	0.01%	836
2016 Q2	$820K	Sell	21,152 -555	-3%	-$23K	0.05%	410
2016 Q1	$834K	Buy	21,707 +10,083	+87%	+$351K	0.05%	411
2015 Q4	$507K	Buy	11,624 +981	+9%	+$48.7K	0.03%	574
2015 Q3	$426K	Buy	10,643 +3,953	+59%	+$173K	0.02%	611
2015 Q2	$361K	Buy	+6,690	New	+$355K	0.02%	746

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Allied Advisory Services's JUNO Position: Q4 2016 in Review

First Allied Advisory Services sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 8,136 shares — an estimated $244K sold.

First Allied Advisory Services first reported a position in JUNO in Q2 2015 and held it in 6 quarters. The position peaked at $834K in Q1 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

First Allied Advisory Services reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
First Allied Advisory Services sold 8,136 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $244K.
First Allied Advisory Services first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
First Allied Advisory Services's Juno Therapeutics, Inc. position peaked at $834K in Q1 2016.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on First Allied Advisory Services's 13F filing for Q4 2016, filed 13 Feb 2017.